MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.87 -7.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.85

Max

2.94

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Aktsiakasum	-0.21
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+328.13% upside

Turustatistika
By TradingEconomics
Turukapital	196M 743M
Eelmine avamishind	10.29
Eelmine sulgemishind	2.87

Uudiste sentiment

By Acuity

60%

40%

309 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4. jaan 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

4. jaan 2026, 23:40 UTC

Market Talk

Uudisväärsed sündmused

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4. jaan 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 23:17 UTC

Uudisväärsed sündmused

Spot Gold Rises 0.8% to $4,365.24/oz

4. jaan 2026, 23:16 UTC

Uudisväärsed sündmused

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4. jaan 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4. jaan 2026, 23:13 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4. jaan 2026, 23:12 UTC

Market Talk

Uudisväärsed sündmused

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4. jaan 2026, 21:00 UTC

Tulu

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3. jaan 2026, 18:59 UTC

Uudisväärsed sündmused

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 17:42 UTC

Uudisväärsed sündmused

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3. jaan 2026, 17:40 UTC

Uudisväärsed sündmused

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 16:10 UTC

Uudisväärsed sündmused

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3. jaan 2026, 15:53 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 15:03 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 14:10 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 12:16 UTC

Uudisväärsed sündmused

U.S. Captures Maduro, Trump Says -- Barrons.com

3. jaan 2026, 09:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

3. jaan 2026, 09:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

3. jaan 2026, 00:43 UTC

Omandamised, ülevõtmised, äriostud

Research Reports -- Barrons.com

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

328.13% tõus

12 kuu keskmine prognoos

Keskmine 12.33 USD 328.13%

Kõrge 15 USD

Madal 10 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

309 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.